Le guide de référence sur l'édition génomique.
★
Menu
Accueil Apprendre Actualités Demandez à l'Atlas
Explorer Technologies Maladies Traitements Essais cliniques Entreprises Scientifiques Gènes Recherche Institutions
Au-delà de la médecine Agriculture Éthique Investissement Carte du monde
Apprendre & Outils Commencer ici Glossaire A–Z Comparer les technologies Chronologie Listes & Classements Agents IA ★ Enregistré API
À propos À propos de nous Méthodologie Sources de données Politique éditoriale Contact Avertissements

🧭 Vue guidée
Nouveau en génétique ? Nous expliquons chaque terme au fil de votre navigation, en langage clair. Les mêmes pages, avec l'aide intégrée.

⚡ Point de vue d'expert
Vous connaissez déjà la biologie. Uniquement le contenu — clair et concis, sans explications supplémentaires. C'est l'affichage par défaut.

Langue de l'interface
Mode clair

Treatment · Inherited blindness

EDIT-101 (Brilliance)

The first CRISPR therapy injected directly into a human organ — scientifically encouraging, and discontinued because the eligible population was too small.

Discontinued in vivoeyediscontinuedCEP290
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Explication simple

EDIT-101 was injected under the retina to cut out a faulty piece of a gene causing a severe inherited blindness. Some patients saw meaningfully better. The programme was then stopped — not because it failed, but because so few people in the world have that exact mutation that developing it further did not make commercial sense. It is the clearest example in the field of good science ending for economic reasons.

Aller plus loin

EDIT-101 delivered SpCas9 and dual guides by subretinal AAV5 injection to excise the intronic CEP290 c.2991+1655A>G variant causing Leber congenital amaurosis type 10. The Phase 1/2 BRILLIANCE trial reported clinically meaningful vision improvement in a subset of participants with an acceptable safety profile, published in the New England Journal of Medicine. Editas discontinued development, citing the small eligible population, and subsequently reset its pipeline around in vivo cardiovascular targets.

Sources

Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas9

Diseases

Inherited Blindness

Clinical Trials

Single Ascending Dose Study of EDIT-101 in Participants With Leber Congenital Amaurosis Type 10

Genes

CEP290

Companies

Editas Medicine
Information éducative uniquement Cette page est une ressource de référence, et non un conseil médical. L'état de la recherche et des autorisations réglementaires évolue ; vérifiez la date de dernière mise à jour ci-dessus et confirmez tout élément important auprès des sources primaires indiquées.